全文获取类型
收费全文 | 32621篇 |
免费 | 1850篇 |
国内免费 | 898篇 |
专业分类
耳鼻咽喉 | 336篇 |
儿科学 | 707篇 |
妇产科学 | 1136篇 |
基础医学 | 8203篇 |
口腔科学 | 895篇 |
临床医学 | 1953篇 |
内科学 | 4005篇 |
皮肤病学 | 547篇 |
神经病学 | 1886篇 |
特种医学 | 596篇 |
外科学 | 1687篇 |
综合类 | 3153篇 |
现状与发展 | 4篇 |
预防医学 | 4181篇 |
眼科学 | 327篇 |
药学 | 3417篇 |
3篇 | |
中国医学 | 439篇 |
肿瘤学 | 1894篇 |
出版年
2024年 | 52篇 |
2023年 | 470篇 |
2022年 | 970篇 |
2021年 | 1290篇 |
2020年 | 1110篇 |
2019年 | 939篇 |
2018年 | 899篇 |
2017年 | 1005篇 |
2016年 | 920篇 |
2015年 | 1040篇 |
2014年 | 1849篇 |
2013年 | 1970篇 |
2012年 | 1603篇 |
2011年 | 1908篇 |
2010年 | 1460篇 |
2009年 | 1514篇 |
2008年 | 1568篇 |
2007年 | 1443篇 |
2006年 | 1286篇 |
2005年 | 1081篇 |
2004年 | 958篇 |
2003年 | 889篇 |
2002年 | 648篇 |
2001年 | 644篇 |
2000年 | 610篇 |
1999年 | 555篇 |
1998年 | 559篇 |
1997年 | 524篇 |
1996年 | 545篇 |
1995年 | 556篇 |
1994年 | 528篇 |
1993年 | 439篇 |
1992年 | 421篇 |
1991年 | 358篇 |
1990年 | 321篇 |
1989年 | 285篇 |
1988年 | 260篇 |
1987年 | 209篇 |
1986年 | 170篇 |
1985年 | 250篇 |
1984年 | 239篇 |
1983年 | 145篇 |
1982年 | 140篇 |
1981年 | 131篇 |
1980年 | 116篇 |
1979年 | 109篇 |
1978年 | 78篇 |
1977年 | 65篇 |
1976年 | 55篇 |
1974年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
目的:了解2011-2017年四川省三州地区卫生人力资源配置现状,为三州地区卫生人力资源的合理配置提供参考。方法:利用千人卫生人力资源拥有量指标、基尼系数和卫生人力资源密度指数(HRDI)分析卫生人力资源配置现状及其公平性。结果:三州地区千人卫生人力资源拥有量呈增长趋势;基尼系数大多超过0.4,仅护士按人口分布的基尼系数较小;卫生人力资源密度指数较小,需要量、缺乏量及缺乏比例均较大。结论:三州地区卫生人力得到一定程度改善;但配置公平性较差,尤其按地理、经济分布很不均衡;医护人员短缺,需要重点投入。 相似文献
3.
内脏利什曼病是全球被忽视的传染病之一,危害严重。而利什曼原虫-人类免疫缺陷病毒(human immunodeficiency virus,HIV)合并感染对流行地区造成的威胁更甚。利什曼原虫与HIV存在相互作用,合并感染者在临床表现、诊断及治疗方面具有一定特殊性,其病死率及复发率均高于HIV阴性的内脏利什曼病患者。本文对利什曼原虫-HIV合并感染患者的临床表现、诊断和治疗进展进行综述。 相似文献
4.
5.
《Clinical nutrition (Edinburgh, Scotland)》2020,39(4):1264-1275
- Download : Download high-res image (110KB)
- Download : Download full-size image
6.
人类微生物群是由寄生在人体上皮屏障的细菌和其他微生物组成的,其中大部分位于肠道内,与宿主之间形成共生的关系。机体肠道微生物的组成虽然受到年龄、饮食、生活方式等因素的影响,但在正常生理情况下是相对稳定的。近年来,肠道菌群与恶性肿瘤的关系越来越受到重视。肠道菌群不但能够维持局部稳态,还能调节机体代谢、炎症和免疫等生理过程。有研究表明,微生物群,特别是肠道菌群能够显著调节机体对癌症治疗的反应性以及机体对毒副反应的敏感性。检查肠道菌群中各菌种之间的比例可作为筛查恶性肿瘤的新方法。本文将综述微生物群具有影响肿瘤的发生发展、抗肿瘤治疗疗效以及药物不良反应的证据,以及其中所涉及的微生物种类,从而为恶性肿瘤精准治疗提供证据。 相似文献
7.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
8.
9.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献10.